MPT: VAMPIRE Results Confirm Benefit of Distal Protection

ACC Conference Reporter

TCT 2017 | DENVER — A distal embolic protection device made no reflows less common during percutaneous coronary intervention (PCI), which translated into improved in-hospital adverse event rates, according to the VAMPIRE 3 trial. Read More >>>

Keywords: Transcatheter Cardiovascular Therapeutics, TCT17


< Back to Listings